Skip to main content
Vitrolife logo

Vitrolife — Investor Relations & Filings

Ticker · VITR ISIN · SE0011205202 LEI · 5493001WDZMONMSPPR49 ST Manufacturing
Open in API
Filings indexed 656 across all filing types
Latest filing 2012-05-24 Regulatory Filings
Country SE Sweden
Listing ST VITR

About Vitrolife

https://www.vitrolife.com/

Vitrolife is a global company focused on reproductive health, providing medical devices and genetic testing services primarily to In Vitro Fertilization (IVF) clinics. The company develops, produces, and markets a comprehensive portfolio of products and solutions that support the entire assisted reproduction treatment journey, from oocyte retrieval and sperm preparation to fertilization, embryo culture, evaluation, transfer, and cryopreservation. With a strong emphasis on quality control, innovation, and clinical support, Vitrolife aims to improve treatment outcomes and operational efficiency for its partners. The company also offers educational resources and training for professionals through its Vitrolife Academy.

Recent filings

Filing Released Lang Actions
­­Vitrolife utsedd till vinnare av SwedenBIO Award 2012
Regulatory Filings Classification · 95% confidence The document is titled "Pressmeddelande" (Press Release) and announces that Vitrolife has won the SwedenBIO Award 2012. It contains company news, a quote from the CEO, and contact information. The final paragraph states that Vitrolife is obligated to publish the information according to securities market laws and specifies the release time. This structure is characteristic of a general corporate announcement or news release that doesn't fit the specific financial reporting categories (like 10-K, ER, IR) or governance filings (like DEF 14A, DVA). Since it is a general regulatory announcement that doesn't fit other specific categories, the most appropriate fallback is Regulatory Filings (RNS). The document length (3888 chars) is short, but it is the primary content, not an announcement *of* another report.
2012-05-24 Swedish
Kommuniké från årsstämma i Vitrolife AB (publ)
AGM Information Classification · 99% confidence The document is titled "Kommuniké från årsstämma i Vitrolife AB (publ)" (Communication from the Annual General Meeting in Vitrolife AB (publ)) and details the resolutions passed at the meeting held on April 19th, including dividend approval, board member re-elections, and authorization for share issuance/repurchase. This content directly relates to the proceedings and outcomes of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R). The document length is short (3697 chars), but it contains the substantive results, not just an announcement that results are available, making AGM-R more specific than RPA or RNS.
2012-04-20 Swedish
Report from Annual General Meeting of Vitrolife AB (publ)
AGM Information Classification · 98% confidence The document is explicitly titled "Report from Annual General Meeting of Vitrolife AB (publ)" and details decisions made at the meeting held on April 19, 2012. Key items include the approval of the dividend, election of board members, and authorization for share acquisition/issuance. This content directly corresponds to the information typically summarized in an AGM report or announcement. Since the text summarizes the outcomes rather than being a lengthy presentation or a formal voting result declaration, the most appropriate classification is AGM-R (AGM Information). The document length (4216 chars) is substantial enough to be the report summary itself, not just a brief announcement of publication (RPA/RNS).
2012-04-20 English
Interim / Quarterly Report 2012
Interim / Quarterly Report Classification · 100% confidence The document is a 'delårsrapport' (interim report) for Vitrolife AB covering the period January-March 2012. It contains comprehensive financial statements, key performance indicators (KPIs), management commentary, and detailed breakdowns of business segments (Fertility and Transplantation). It is not an announcement of a report, but the report itself, containing substantive financial data. Q1 2012
2012-04-19 Swedish
Interim / Quarterly Report 2012
Interim / Quarterly Report Classification · 100% confidence The document is titled 'interim report january-march 2012' and contains detailed financial statements, key figures, CEO comments, and analysis of business performance for the first quarter of 2012. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2012
2012-04-19 English
Thomas Axelsson appointed CEO of Vitrolife
Board/Management Information Classification · 99% confidence The document is a press release announcing the appointment of Thomas Axelsson as the new CEO of Vitrolife, effective immediately after serving as Acting CEO. This constitutes an announcement of a change in senior management. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document is short and clearly fits this specific category.
2012-04-18 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.